Sugi Predict

Sugi Predict / Compounds / SCHEMBL952927

SCHEMBL952927

SCHEMBL952927

O=C(CCl)N1CCCC1=O

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 2/20 0.70
▸ TDP1 Q9NUW8 3/20 0.47
▸ POLB P06746 1/20 0.47
▸ CASP6 P55212 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ TSHR P16473 1/20 0.41
▸ KMT2A Q03164 4/20 0.40
▸ KDM4E B2RXH2 1/20 0.40
▸ MEN1 O00255 1/20 0.40
▸ CYP1A2 P05177 1/20 0.40
▸ CYP2D6 P10635 1/20 0.40
▸ MAPT P10636 1/20 0.40
▸ THRB P10828 1/20 0.40
▸ CYP2C9 P11712 1/20 0.40
▸ CYP2C19 P33261 1/20 0.40
▸ RECQL P46063 1/20 0.40
▸ BLM P54132 1/20 0.40
▸ RAB9A P51151 1/20 0.39
▸ NPC1 O15118 1/20 0.37
▸ TTR P02766 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10608673 0.94 LMNA (0.62) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL10607516 0.92 LMNA (0.60) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL9621839 0.83 LMNA (0.76) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL5182541 0.83 LMNA (1.00) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL20107836 0.81 LMNA (0.73) LMNATDP1POLBCASP6L3MBTL1
Methylene Chloride SCHEMBL11620747 0.79 LMNA (0.59) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL9333110 0.79 LMNA (0.70) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL5147430 0.79 LMNA (0.70) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL5180649 0.79 LMNA (0.84) LMNATDP1POLBCASP6L3MBTL1
SCHEMBL15886469 0.79 LMNA (0.70) LMNATDP1POLBCASP6L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1243581-B1 Pyridinium compounds useful for the treatment of AGE-related diseases TORRENT PHARMACEUTICALS LTD (IN) 2005-07-13 — — EP claimed
CN-1629142-A Piperazine-bridged tacrine binary derivatives and synthesis method thereof BEIJING INST TECHNOLOGY (CN) 2005-06-22 — — CN claimed
CN-1148351-C Compound for curing vascular complication, its preparing method and treating use ������˹ҩƷ��˾ 2004-05-05 — — CN claimed
US-6608094-B2 Breaking preformed AGE TORRENT PHARMACEUTICALS LTD. (IN) 2003-08-19 — — US claimed
US-8669266-B2 Quinoline-carboxamide derivatives as P2Y12 antagonists SANOFI (FR) 2014-03-11 — — US disclosed
US-8426420-B2 Heterocyclic pyrazole-carboxamidesas P2Y12 antagonists SANOFI (FR) 2013-04-23 — — US disclosed
EP-2238128-B1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFI SA (FR) 2012-08-22 — — EP disclosed
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2011-01-27 — — US disclosed
EP-2238128-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-10-13 — — EP disclosed
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS SANOFI-AVENTIS (FR) 2010-06-03 — — US disclosed
EP-2148871-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS Sanofi-Aventis (FR) 2010-02-03 — — EP disclosed
WO-2009080226-A2 HETEROCYCLIC PYRAZOLE-CARBOXAMIDES AS P2Y12 ANTAGONISTS SANOFIS-AVENTIS (FR) 2009-07-02 — — WO disclosed
US-20010018524-A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof TORRENT PHARMACEUTICALS LTD. (IN) 2001-08-30 — — US disclosed
US-5952283-A DETERGENT COMPRISING A PEROXY COMPOUND AND A BLEACH ACTIVATOR OF GIVEN FORMULA, SUCH AS (TRIALKYLAMMONIUM)ACETYLPYRROLIDONE CHLORIDES AND (TRIALKYLAMMONIUM)ACETYL-IMIDAZOLE CHLORIDES; BETTER BLEACHING ACTION AND FEWER SYNTHESIS STEPS CLARIANT GMBH (DE) 1999-09-14 — — US disclosed
US-5877325-A QUATERNARY AMMONIUM ACETYL-LACTAMS AND -CYCLIC AMIDINES (IMIDAZOLE) HOECHST AKTIENGESELLSCHAFT (DE) 1999-03-02 — — US disclosed
CN-1038511-C Imidazopyridine MERCK PATENT GMBH (DE) 1998-05-27 — — CN disclosed
EP-0816336-A1 Quaternary ammonium compounds as bleach activators and their preparation Clariant GmbH (DE) 1998-01-07 — — EP disclosed
CN-1082545-A Imidazopyridine MERCK PATENT GMBH (DE) 1994-02-23 — — CN disclosed
US-4808620-A ANTIINFLAMMATORY, ANALGESICS, ANTIPYRETIC, ANTIALLERGENS, ANTIARTHRITIC, ANTIRHEUMATIC AGENTS YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 1989-02-28 — — US disclosed
EP-0254241-A1 Pyrazolopyridine compounds, their preparation and use Yoshitomi Pharmaceutical Industries, Ltd. (JP) 1988-01-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100135999-A1 QUINOLINE-CARBOXAMIDE DERIVATIVES AS P2Y12 ANTAGONISTS P2RY12, P2RY1, P2RY2 LMNA 977/4885TDP1 1942/4885POLB 1874/4885
US-20010018524-A1 Novel compounds for the management of aging-related and diabetic vascular complications, process for their preparation and therapeutic uses thereof AGER, GLA, RBP1 LMNA 635/4885TDP1 305/4885POLB 632/4885
US-20110021537-A1 HETEROCYCLIC PYRAZOLE-CARBOXAMIDESAS P2Y12 ANTAGONISTS P2RY1, P2RY12, P2RY11 LMNA 1671/4885TDP1 1823/4885POLB 2236/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.